Nifedipine 20mg Tablet
Description
NIFEROOT-20
Nifedipine Sustained Release 20 mg Tablets
Division: DIABGLYM
Composition
Each sustained-release tablet contains:
Nifedipine IP — 20 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Sustained-release oral tablet
Product Description
NIFEROOT-20 contains Nifedipine Sustained Release 20 mg, a long-acting dihydropyridine calcium channel blocker formulated for the effective management of hypertension, chronic stable angina, vasospastic angina, and long-term cardiovascular risk reduction. The sustained-release formulation provides gradual drug release, ensuring prolonged blood pressure control, improved coronary blood flow, and reduced cardiovascular workload.
Nifedipine is widely prescribed in cardiology and internal medicine for patients with essential hypertension, isolated systolic hypertension, coronary artery disease, and peripheral vascular disorders. It helps reduce systolic and diastolic blood pressure, improve myocardial oxygen supply, decrease peripheral vascular resistance, and lower the risk of cardiovascular complications.
NIFEROOT-20 is particularly beneficial for patients initiating sustained-release nifedipine therapy, those requiring moderate-dose antihypertensive treatment, once-daily blood pressure control, angina prophylaxis, and long-term cardiovascular protection.
Technical Knowledge of Nifedipine Sustained Release
Nifedipine selectively inhibits L-type calcium channels in vascular smooth muscle and coronary arteries. By reducing calcium influx into vascular smooth muscle cells, it produces arterial vasodilation, decreases peripheral vascular resistance, improves coronary artery blood flow, and reduces myocardial oxygen demand.
The sustained-release formulation provides controlled drug delivery over an extended period, maintaining stable plasma concentrations and minimizing fluctuations associated with immediate-release formulations. This results in prolonged antihypertensive efficacy and improved tolerability.
Mechanism of Action
Nifedipine blocks L-type calcium channels, relaxes vascular smooth muscle, dilates peripheral and coronary arteries, reduces systemic vascular resistance, lowers blood pressure, improves coronary perfusion, and decreases myocardial oxygen demand.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Provides sustained 24-hour blood pressure control
Improves coronary blood flow
Reduces peripheral vascular resistance
Helps prevent chronic angina attacks
Supports long-term cardiovascular protection
Convenient sustained-release dosing
Suitable for long-term hypertension and angina management under medical supervision
Clinical Applications
NIFEROOT-20 is commonly prescribed for essential hypertension, isolated systolic hypertension, chronic stable angina, vasospastic angina, coronary artery disease, peripheral vascular disorders, and long-term cardiovascular risk reduction.
Facts About Nifedipine
Nifedipine is one of the most extensively studied calcium channel blockers and has proven efficacy in hypertension and chronic angina management. Sustained-release formulations provide prolonged therapeutic activity, improved patient adherence, and more stable blood pressure control. The 20 mg sustained-release strength is commonly used for initiation and maintenance therapy in patients requiring individualized antihypertensive treatment.
Key Facts
Long-acting calcium channel blocker
Nifedipine Sustained Release 20 mg for sustained blood pressure control
Provides prolonged coronary vasodilation
Effective in hypertension and chronic angina
Supports long-term cardiovascular protection
Evidence-based calcium channel blocker therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
NIFEROOT-20 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose NIFEROOT-20 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Nifedipine Sustained Release 20 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented sustained-release formulation
Controlled-release tablet manufacturing technology
Blister and Alu-Alu packaging options
NIFEROOT-20 from DIABGLYM combines sustained blood pressure control, improved coronary perfusion, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nifedipine sustained-release formulation.
